News | August 12, 2021
Natco Pharma PAT at Rs 75 crore for Q1FY22
The company has strong product launches both in India and overseas
The company has strong product launches both in India and overseas
It had an estimated market size of US $ 32 million as of June 2021
Arrow is the marketing partner in US
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated
